SWX: RLF Statistics

Total Valuation

Relief Therapeutics Holding has a market cap or net worth of CHF 46.78 million. The enterprise value is 38.46 million.

Market Cap	46.78M
Enterprise Value	38.46M

Important Dates

The next estimated earnings date is Tuesday, April 1, 2025.

Earnings Date	Apr 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Relief Therapeutics Holding has 12.54 million shares outstanding. The number of shares has increased by 14.39% in one year.

Current Share Class	n/a
Shares Outstanding	12.54M
Shares Change (YoY)	+14.39%
Shares Change (QoQ)	+12.10%
Owned by Insiders (%)	0.70%
Owned by Institutions (%)	11.64%
Float	9.56M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.42
PB Ratio	0.95
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.83
EV / Sales	4.47
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.70

Financial Position

The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.05.

Current Ratio	3.09
Quick Ratio	2.45
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	-0.23
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -64.38% and return on invested capital (ROIC) is -10.23%.

Return on Equity (ROE)	-64.38%
Return on Assets (ROA)	-7.83%
Return on Invested Capital (ROIC)	-10.23%
Return on Capital Employed (ROCE)	-18.63%
Revenue Per Employee	175,469
Profits Per Employee	-943,653
Employee Count	49
Asset Turnover	0.09
Inventory Turnover	6.56

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +129.81% in the last 52 weeks. The beta is -14.50, so Relief Therapeutics Holding's price volatility has been lower than the market average.

Beta (5Y)	-14.50
52-Week Price Change	+129.81%
50-Day Moving Average	4.27
200-Day Moving Average	2.73
Relative Strength Index (RSI)	45.20
Average Volume (20 Days)	26,822

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Relief Therapeutics Holding had revenue of CHF 8.60 million and -46.24 million in losses. Loss per share was -3.70.

Revenue	8.60M
Gross Profit	5.90M
Operating Income	-12.33M
Pretax Income	-51.54M
Net Income	-46.24M
EBITDA	-9.81M
EBIT	-12.33M
Loss Per Share	-3.70

Full Income Statement

Balance Sheet

The company has 10.73 million in cash and 2.42 million in debt, giving a net cash position of 8.31 million or 0.66 per share.

Cash & Cash Equivalents	10.73M
Total Debt	2.42M
Net Cash	8.31M
Net Cash Per Share	0.66
Equity (Book Value)	49.27M
Book Value Per Share	3.92
Working Capital	9.95M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -10.31 million and capital expenditures -77,000, giving a free cash flow of -10.39 million.

Operating Cash Flow	-10.31M
Capital Expenditures	-77,000
Free Cash Flow	-10.39M
FCF Per Share	-0.83

Full Cash Flow Statement

Margins

Gross Margin	68.56%
Operating Margin	-143.38%
Pretax Margin	-599.43%
Profit Margin	n/a
EBITDA Margin	-114.13%
EBIT Margin	-143.38%
FCF Margin	n/a

Dividends & Yields

Relief Therapeutics Holding does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.39%
Shareholder Yield	-14.39%
Earnings Yield	-98.85%
FCF Yield	-22.21%

Stock Splits

The last stock split was on May 5, 2023. It was a reverse split with a ratio of 0.0025.

Last Split Date	May 5, 2023
Split Type	Reverse
Split Ratio	0.0025

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a